骨化三醇联合依降钙素治疗骨质疏松症的疗效及对患者骨代谢的影响
DOI:
CSTR:
作者:
作者单位:

北京市怀柔区中医医院

作者简介:

通讯作者:

中图分类号:

基金项目:

北京市怀柔区卫生健康委员会科研项目 2022-C-001)


The efficacy of calcitriol combined with elcatonin in treating osteoporosis and its impact on bone metabolism in patients
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
    摘要:

    目的 探究骨化三醇(Cal)联合依降钙素治疗骨质疏松症(OP)的疗效及对患者骨代谢的影响。方法 选取2022年6月至2024年6月北京市怀柔区中医医院收治的100例老年OP患者作为研究对象,按随机数字表法分为标准组(50例)和联合组(50例)。其中标准组采用口服Cal软胶囊,联合组在标准组的基础上加用依降钙素注射液,两组疗程均为3个月,随访12个月。比较两组患者临床疗效、以及治疗前、治疗后3个月的骨代谢[骨碱性磷酸酶(BALP)、抗酒石酸酸性磷酸酶(TRACP)、骨钙素(OC)、I型胶原交联C-末端肽(CTX)]、骨密度(BMD)、骨疼痛评分、生活质量评分及不良反应发生情况。结果 联合组的治疗效果显著优于标准组(94.00%,70.00%,P<0.05);治疗后,两组BALP、OC、BMD水平、生活质量评分均较治疗前上升,且联合组显著高于标准组(P<0.05);两组TRACP、CTX水平、骨疼痛评分均较治疗前降低,且联合组显著低于标准组(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。随访12个月,两组骨折发生率比较,差异无统计学意义(P>0.05)。结论 Cal联合依降钙素治疗OP患者有较好的临床疗效,可调节骨代谢指标,可有效调节骨代谢,增加骨密度,缓解疼痛并改善生活质量,且安全性高。

    Abstract:

    Objective: To investigate the efficacy of calcitriol (Cal) combined with elcatonin on osteoporosis (OP) and its impact on bone metabolism in patients. Methods: One hundred elderly OP patients admitted to Huairou District Traditional Chinese Medicine Hospital from June 2022 to June 2024 were enrolled as the research subjects and randomly assigned into criterion group (50 cases) and joint group (50 cases) complying with random number table. The criterion group received oral Cal soft capsules, while the joint group received additional elcatonin injection on top of the criterion group. The treatment course for both groups was 3 months, with a follow-up of 12 months. The efficacy, bone metabolism [bone alkaline phosphatase (BALP), tartrate resistant acid phosphatase (TRACP), osteocalcin (OC), type I collagen cross-linked C-terminal peptide (CTX)], bone mineral density (BMD), bone pain score, quality of life score before treatment and after 3 months of treatment, and incidence of adverse reactions were compared between the two groups. Results The therapeutic effect of the joint group was significantly better than that of the criterion group (94.00%, 70.00%, P<0.05). After treatment, the BALP, OC, BMD, and quality of life scores of both groups significantly increased compared with those before treatment, and the joint group was significantly higher than the criterion group (P<0.05). The TRACP, CTX, and bone pain scores of both groups significantly decreased compared with those before treatment, and the joint group was prominently lower than the criterion group (P<0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P>0.05). At 12-month follow-up, there was no statistically significant difference in fracture incidence between the two groups (P>0.05). Conclusion: The combination of Cal and elcatonin has good efficacy in treating OP patients. It can regulate bone metabolism indicators, effectively regulate bone metabolism, increase bone density, relieve pain and improve quality of life, and has high safety.

    参考文献
    相似文献
    引证文献
引用本文
分享
相关视频

文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2026-07-01
  • 最后修改日期:2026-09-07
  • 录用日期:2026-11-04
  • 在线发布日期:
  • 出版日期:
文章二维码